自體免疫疾病治療市場：依疾病、藥物和地區分類

預計到2026年，自體免疫疾病治療市場規模將達81.4億美元，2033年將達136億美元。預計從2026年到2033年，該市場將以7.6%的複合年成長率成長。

該市場正經歷持續成長，主要促進因素包括自體免疫疾病盛行率上升、診斷率提高、生物製藥和標靶治療的應用日益廣泛，以及免疫調節療法的不斷進步。類風濕性關節炎、多發性硬化症、乾癬、發炎性腸道疾病、全身性紅斑性狼瘡、自體免疫甲狀腺疾病和1型糖尿病等自體免疫疾病通常需要長期甚至終身治療，因此對藥物治療的需求持續旺盛。

治療方案包括免疫抑制劑、抗發炎藥物、皮質類固醇、非類固醇消炎劑(NSAIDs) 以及其他療法，可針對全身性和器官特異性自體免疫疾病。市場正從廣譜免疫抑制療法轉向更具針對性的治療方法，這些方法針對細胞激素、抗體、受體、B細胞路徑和其他疾病特異性免疫機制。這種轉變為那些對傳統皮質類固醇或免疫抑制療法反應不佳的患者提供了更多治療選擇。

標靶口服療法、自體給藥生物製劑、生物相似藥以及CAR-T細胞療法等新型免疫重置療法的進步，正在進一步改變治療模式。這些創新提高了治療的特異性、便利性和長期疾病管理水平，同時為重症或難治性自體免疫疾病患者拓展了治療選擇。

市場動態

由於慢性自體免疫疾病的臨床負擔日益加重，以及對長期疾病管理的需求不斷成長，市場正獲得顯著成長動力。類風濕性關節炎、紅斑性狼瘡、多發性硬化症、發炎性腸道疾病、重症肌無力和自體免疫甲狀腺疾病等疾病通常需要長期藥物治療，這支撐了對免疫抑制劑、皮質類固醇、抗發炎藥物和標靶治療需求。

標靶生技藥品和路徑特異性療法的快速發展和普及是推動市場變革的另一個主要因素。治療方法越來越注重針對特定免疫介質而非普遍的免疫抑制，從而為對傳統療法反應不佳的患者提供了更多選擇。新型生技藥品、生物相似藥、標靶口服療法和患者自行給藥製劑的持續獲批，正在增加多種自體免疫疾病的先進治療選擇。

此外，生物製藥研發活動的活性化、支持生物相似藥開發的監管舉措以及人們對下一代療法的日益關注，也對市場產生了積極影響。新型治療方法，例如CAR-T細胞療法，旨在從根本上重置某些嚴重自體免疫疾病的免疫系統，從而有可能將部分治療方案從持續免疫抑制轉向更持久的疾病管理。同時，患者可自行給藥的生物製劑和標靶口服療法提高了治療的便利性，並推動了自體免疫疾病管理模式逐步轉變為以患者為中心的模式。

由於北美擁有先進的專業醫療基礎設施、生物製藥和標靶免疫療法的高滲透率、活躍的藥物研發以及創新療法的快速應用，預計北美仍將是主要市場。同時，亞太地區預計將經歷相對快速的成長，這得益於生物製藥和生物相似藥的日益普及、專業醫療基礎設施的完善、國內生物製藥的研發以及標靶治療法規核准範圍的擴大。

本次調查的主要特點

• 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
• 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
• 本研究根據公司概況、產品系列、主要亮點、財務績效和策略等參數，對自體免疫疾病治療市場的主要參與者進行了分析。
• 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
• 《自體免疫疾病治療市場》報告的目標受群眾外包括該行業的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 相關人員將能夠透過分析自體免疫疾病治療市場中使用的各種策略矩陣做出更順利的決策。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場概覽

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 促進因素
  • 抑制因子
  • 市場機遇
• 影響分析
• 市場趨勢
• 主要進展
• 產品核准
• 合作關係、併購
• 監理情勢
• PEST分析
• 波特五力分析
• 流行病學
• 穩健的管道分析

第4章 全球自體免疫疾病治療市場：依疾病類型分類，2021-2033年

• 系統
• 器官特異性

第5章 全球自體免疫疾病治療市場：依藥物分類，2021-2033年

• 免疫抑制劑
• 抗發炎藥
• 皮質類固醇
• 非類固醇類抗發炎藥
• 其他

第6章 全球自體免疫疾病治療市場：依地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲國家
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太國家
• 中東
  • GCC
  • 以色列
  • 其他中東國家
• 非洲
  • 北非
  • 中非
  • 南非

第7章 競爭情勢

• 熱圖分析
• 市佔率分析
• 公司簡介
  • Johnson & Johnson
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Active Biotech
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • AutoImmune Inc.
  • Pfizer, Inc.
  • AstraZeneca plc
  • Lupin Limited
  • 4SC AG
  • Amgen, Inc.
  • Bristol-Myers Squibb
• 分析師意見

第8章

• 參考
• 調查方法
• 關於本公司

Autoimmune Disease Treatment Market is estimated to be valued at USD 8.14 Bn in 2026 and is expected to reach USD 13.60 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.6% from 2026 to 2033.

The market is witnessing sustained growth primarily driven by the rising prevalence of autoimmune diseases, increasing diagnosis rates, growing adoption of biologic and targeted therapies, and continued advancements in immunomodulatory treatment approaches. Autoimmune conditions such as rheumatoid arthritis, multiple sclerosis, psoriasis, inflammatory bowel diseases, systemic lupus erythematosus, autoimmune thyroid diseases, and type 1 diabetes often require prolonged or lifelong treatment, supporting recurring demand for pharmacological therapies.

The treatment landscape encompasses immunosuppressants, anti-inflammatory drugs, corticosteroids, nonsteroidal anti-inflammatory drugs, and other therapies, addressing both systemic and organ-specific autoimmune diseases. The market is increasingly transitioning from broad immune suppression toward more targeted therapeutic approaches directed at cytokines, antibodies, receptors, B-cell pathways, and other disease-specific immune mechanisms. This transition is expanding treatment options for patients who demonstrate inadequate responses to conventional corticosteroids and immunosuppressive therapies.

Advancements in targeted oral therapies, self-administered biologics, biosimilars, and emerging immune-reset approaches such as CAR-T cell therapy are further reshaping the treatment paradigm. These innovations are improving treatment specificity, convenience, and long-term disease management while broadening therapeutic options for patients with severe or treatment-refractory autoimmune conditions.

Market Dynamics

The market is gaining significant momentum owing to the increasing clinical burden of chronic autoimmune diseases and the growing requirement for long-term disease management. Conditions such as rheumatoid arthritis, lupus, multiple sclerosis, inflammatory bowel disease, myasthenia gravis, and autoimmune thyroid disorders frequently require prolonged pharmacological intervention, thereby supporting sustained demand for immunosuppressants, corticosteroids, anti-inflammatory drugs, and targeted therapies. Diagnostic gaps also represent an important market factor, as delayed diagnosis can postpone initiation of appropriate treatment and increase the unmet therapeutic need.

The rapid development and adoption of targeted biologics and pathway-specific therapies is another major factor transforming the market. Treatment approaches are increasingly focusing on specific immune mediators rather than generalized immune suppression, thereby expanding options for patients inadequately controlled with traditional therapies. Continuous regulatory approvals of novel biologics, biosimilars, targeted oral therapies, and self-administered formulations are strengthening the availability of advanced treatment options across multiple autoimmune indications.

The market is also benefiting from increasing biopharmaceutical research activity, regulatory initiatives supporting biosimilar development, and growing interest in next-generation therapeutic modalities. Emerging approaches such as CAR-T cell therapy aim to achieve deeper immune-system resetting in selected severe autoimmune diseases, potentially shifting parts of the treatment landscape from continuous immunosuppression toward more durable disease control. At the same time, self-administered biologics and targeted oral therapies are increasing treatment convenience and supporting a gradual transition toward more patient-centric autoimmune disease management.

North America is expected to remain a major market owing to advanced specialty-care infrastructure, high adoption of biologics and targeted immunotherapies, strong pharmaceutical R&D activity, and rapid uptake of innovative treatments. Meanwhile, Asia Pacific is expected to witness comparatively faster growth, supported by expanding availability of biologics and biosimilars, increasing specialty-care infrastructure, domestic biopharmaceutical development, and broader regulatory approvals of targeted therapies.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Autoimmune Disease Treatment Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Johnson & Johnson, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Active Biotech, GlaxoSmithKline plc, Eli Lilly and Company, AutoImmune Inc., Pfizer, Inc. AstraZeneca plc, Lupin Limited, 4SC AG, Amgen, Inc., and Bristol-Myers Squibb.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The Autoimmune Disease Treatment Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Autoimmune Disease Treatment Market

Market Segmentation

• By Disease Type (Revenue, USD Bn, 2021-2033)
• Systemic
• Organ-specific
• By Drug Type (Revenue, USD Bn, 2021-2033)
• Immunosuppressant's
• Anti-Inflammatory Drugs
• Corticosteroids
• Nonsteroidal anti-inflammatory drugs
• Others
• Global Autoimmune Disease Treatment Market, By Region (Revenue, USD Bn, 2021-2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • Central Africa
  • North Africa
• Key Players
• Johnson & Johnson
• Abbott Laboratories
• Hoffmann-La Roche Ltd.
• Active Biotech
• GlaxoSmithKline plc
• Eli Lilly and Company
• AutoImmune Inc.
• Pfizer, Inc.
• AstraZeneca plc
• Lupin Limited
• 4SC AG
• Amgen, Inc.
• Bristol-Myers Squibb

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Disease Type
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Product Approval
• Collaboration/Merge/Acquisition
• Regulatory Landscape
• PEST Analysis
• Porter's Five Forces Analysis
• Epidemiology
• Robust Pipeline Analysis

4. Global Autoimmune Disease Treatment Market, By Disease Type, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022- 2033
  • Segment Trends
• Systemic
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Organ-specific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

5. Global Autoimmune Disease Treatment Market, By Drug Type, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022- 2033
  • Segment Trends
• Immunosuppressant's
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Anti-Inflammatory Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Corticosteroids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Nonsteroidal anti-inflammatory drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

6. Global Autoimmune Disease Treatment Market, By Region, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2022-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • North Africa
    • Central Africa
    • South Africa

7. Competitive Landscape

• Heat Map Analysis
• Market Share Analysis
• Company Profile
  • Johnson & Johnson
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Abbott Laboratories
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • F. Hoffmann-La Roche Ltd.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Active Biotech
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • GlaxoSmithKline plc
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • AutoImmune Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Pfizer, Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • AstraZeneca plc
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Lupin Limited
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • 4SC AG
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Amgen, Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Bristol-Myers Squibb
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
• Analyst Views

8. Section

• References
• Research Methodology
• About Us